Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/127352
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fernández Martínez, Aranzazu | - |
dc.contributor.author | Pascual, Tomás | - |
dc.contributor.author | Perrone, Giuseppe | - |
dc.contributor.author | Morales, Serafín | - |
dc.contributor.author | Haba, Juan de la | - |
dc.contributor.author | González Rivera, Milagros | - |
dc.contributor.author | Galván, Patricia | - |
dc.contributor.author | Zalfa, Francesca | - |
dc.contributor.author | Amato, Michela | - |
dc.contributor.author | Gonzalez, Lucía | - |
dc.contributor.author | Prats de Puig, Miquel | - |
dc.contributor.author | Rojo, Federico | - |
dc.contributor.author | Manso, Luis | - |
dc.contributor.author | Paré, Laia | - |
dc.contributor.author | Alonso, Immaculada | - |
dc.contributor.author | Albanell Mestres, Joan | - |
dc.contributor.author | Vivancos, Ana | - |
dc.contributor.author | González, Antonio | - |
dc.contributor.author | Matito, Judit | - |
dc.contributor.author | González, Sonia | - |
dc.contributor.author | Fernández Ruiz, Pedro Luis | - |
dc.contributor.author | Adamo, Barbara | - |
dc.contributor.author | Muñoz Mateu, Montserrat | - |
dc.contributor.author | Viladot, Margarita | - |
dc.contributor.author | Font, Carme | - |
dc.contributor.author | Aya, Francisco | - |
dc.contributor.author | Vidal Losada, Maria Jesús | - |
dc.contributor.author | Caballero, Rosalía | - |
dc.contributor.author | Carrasco, Eva | - |
dc.contributor.author | Altomare, Vittorio | - |
dc.contributor.author | Tonini, Giuseppe | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Martín, Miguel | - |
dc.date.accessioned | 2019-01-16T19:09:18Z | - |
dc.date.available | 2019-01-16T19:09:18Z | - |
dc.date.issued | 2017-03-28 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/2445/127352 | - |
dc.description.abstract | PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Impact Journals | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.15748 | - |
dc.relation.ispartof | Oncotarget, 2017, vol. 8, num. 13, p. 21930-21937 | - |
dc.relation.uri | https://doi.org/10.18632/oncotarget.15748 | - |
dc.rights | cc-by (c) Fernandez, Aranzazu et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.classification | Expressió gènica | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Biochemical markers | - |
dc.subject.other | Gene expression | - |
dc.title | Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 675969 | - |
dc.date.updated | 2019-01-16T19:09:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28423537 | - |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
675969.pdf | 3.15 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License